• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Duration of symptomatic stroke and successful reperfusion with endovascular thrombectomy for anterior circulation large vessel occlusive stroke
Conclusion In a real-world cohort of acute ischemic stroke patients with anterior circulation occlusion treated with endovascular therapy, longer duration of symptomatic stroke is associated with lower rates of successful reperfusion and reperfusion on the first pass.
Source: Journal of NeuroInterventional Surgery - November 18, 2021 Category: Neurosurgery Authors: de Havenon, A., Alexander, M. D., Nogueira, R. G., Haussen, D. C., Castonguay, A. C., Linfante, I., Johnson, M. A., Nguyen, T. N., Mokin, M., Zaidat, O. O. Tags: Ischemic stroke Source Type: research

Acute Treatment of Ischemic Stroke
This article outlines the evidence to support intravenous thrombolysis with alteplase and tenecteplase, thrombolysis in the setting of DWI/flair mismatch, endovascular treatment in the 6-hour and 6- to 24-hour window, and the use of telemedicine in acute stroke. Current controversies and ongoing trials within endovascular treatment are also detailed. Case presentations are included to provide clinical context and the application of data to practice.
Source: Neurologic Clinics - November 17, 2021 Category: Neurology Authors: Stephanie Lyden, Jana Wold Source Type: research

Cerebrovascular Risk Profiles in a Saudi Arabian Cohort of Young Stroke Patients
Conclusion: Cerebrovascular risk profiles and stroke etiologies in our cohort of young stroke patients differ from those of previous cohorts, suggesting the need for tailored prevention strategies that take into account local epidemiological data on cerebrovascular health.
Source: Frontiers in Neurology - November 12, 2021 Category: Neurology Source Type: research

Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study
AbstractStroke is the third leading cause of death in the United States and the leading cause of adult disability. Despite enormous research efforts including many clinical trials, tissue plasminogen activator (tPA) remains the only FDA-approved treatment for acute ischemic stroke. Unfortunately, only 1 –3% of stroke patients in the US receive this therapy because of the narrow time window and severe side effects for using tPA. The most deadly and damaging side effect is the risk of intracranial bleeding or hemorrhage. For that reason, the dose of tPA and its overall administration are under tigh t control, which may com...
Source: Journal of Thrombosis and Thrombolysis - November 10, 2021 Category: Hematology Source Type: research

Epidemiology of stroke in the last decade: a systematic review
CONCLUSION: There are few studies that analyse the incidence of CVD and even fewer that analyse its evolution. The overall median remains high, although the figures are heterogeneous across studies. Worldwide the trend is towards its decrease, and there are geographical areas, especially in Asia, with an alarming upward trend.PMID:34676530 | DOI:10.33588/rn.7309.2021138
Source: Revista de Neurologia - October 22, 2021 Category: Neurology Authors: F Purroy N Montal à Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20